| SPECIAL FEATURE | Cell Therapy News is now on Facebook. Join us! Follow us on Twitter! @MammaryCell Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at info@connexoncreative.com |
| SCIENCE NEWS | Destined for Disease: Breast Cancer Mutation Regulates Cell Fate A new study sheds light on why individuals who inherit a particular family of mutations have a high risk of developing a very aggressive form of breast cancer. [Press release from ScienceDaily discussing online prepublication in Cell Stem Cell] Limited Lymph Node Removal for Certain Breast Cancer Does Not Appear to Result in Poorer Survival Among patients with early-stage breast cancer that had spread to a nearby lymph node and who received treatment that included lumpectomy and radiation therapy, women who just had the sentinel lymph node removed did not have worse survival than women who had more extensive axillary lymph node dissection, according to a study. [Press release from ScienceDaily discussing online prepublication in The Journal of the American Medical Association] |
| INDUSTRY NEWS | Johns Hopkins’ Andrew Ewald Honored by Anatomy Society Andrew Ewald, Ph.D., who studies how cells build organs and how these same cellular processes can contribute to breast cancer metastasis, will receive the American Association of Anatomists’ 2011 Morphological Sciences Award for his “outstanding contributions to the field of epithelial morphogenesis.” [Johns Hopkins Medicine Press Release] UCLB & BD Reach Exclusive License Agreement UCL Business (UCLB) and BD (Becton, Dickinson and Company) announced an agreement aimed at improving the early detection of ovarian and breast cancers to ultimately enable earlier and more effective treatment. [University College London (UCL) Business Press Release] Pfizer Said to Pay $330 Million in Prempro Settlement Pfizer Inc. agreed to pay about $330 million to resolve claims that its Prempro menopause drug caused breast cancer, in the first large-scale settlements in eight years of litigation, two people familiar with the accords said. [Bloomberg BusinessWeek] |
|
|
|